Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Obtains Approval For Macular Degeneration Drug Macugen In Japan

This article was originally published in PharmAsia News

Executive Summary

Pfizer Japan announced it obtained approval for age-related macular degeneration drug Macugen (pegaptanib) intravitreal injection kit 0.3mg. A treatment for wet AMD, Macugen was approved by U.S. FDA in December 2004. In Japan, the drug was designated as an orphan drug in July 2004 and Pfizer applied for approval in March 2007. The risk of AMD increases as a person ages and in Japan and Europe, the number of AMD patients is estimated to increase. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel